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A B S T R A C T
Purpose
To investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after
allogeneic stem-cell transplantation (alloSCT) for myelodysplastic syndrome (MDS).
Patients and Methods
Of the 265 consecutive patients who underwent alloSCT for MDS between October 2005 and
December 2009, 163 had received cytoreductive treatment prior to transplantation, including
induction chemotherapy (ICT) alone (ICT group; n  98), AZA alone (AZA group; n  48), or AZA
preceded or followed by ICT (AZA-ICT group; n  17). At diagnosis, 126 patients (77%) had an
excess of marrow blasts, and 95 patients (58%) had intermediate-2 or high-risk MDS according to
the International Prognostic Scoring System (IPSS). Progression to more advanced disease before
alloSCT was recorded in 67 patients. Donors were sibling (n  75) or HLA-matched unrelated
(10/10; n  88). They received blood (n  142) or marrow (n  21) grafts following either
myeloablative (n  33) or reduced intensity (n  130) conditioning.
Results
With a median follow-up of 38.7 months, 3-year outcomes in the AZA, ICT, and AZA-ICT groups were
55%, 48%, and 32% (P  .07) for overall survival (OS); 42%, 44%, and 29% (P  .14) for event-free
survival (EFS); 40%, 37%, and 36% (P  .86) for relapse; and 19%, 20%, and 35% (P  .24) for
nonrelapse mortality (NRM), respectively. Multivariate analysis confirmed the absence of statistical
differences between the AZA and the ICT groups in terms of OS, EFS, relapse, and NRM.
Conclusion
With the goal of downstaging underlying disease before alloSCT, AZA alone led to outcomes
similar to those for standard ICT.
J Clin Oncol 30:4533-4540. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Allogeneic hematopoietic stem-cell transplantation
(alloSCT) remains the only potentially curative
available therapeutic approach in patients with
myelodysplastic syndrome (MDS). Despite the benefi-
cial effects of alloSCT, these patients are at substantial
risk of relapse after transplantation, especially in case of
reduced-intensity conditioning (RIC). Whether a
treatment should be administered before transplanta-
tion and the type of such treatment are still controver-
sial. In particular, acute myeloid leukemia (AML)
induction chemotherapy (ICT) has been recom-
mended in young patients when MDS was associated
withmorethan5%marrowblasts,1,2 butthisapproach
is associated with toxicities that could prohibit pro-
ceeding to transplantation and may interfere with the
transplantation outcome.
Demethylating agents or DNMTi (DNA methyl-
transferase inhibitors), including azacitidine (AZA)
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and decitabine, have emerged as new therapeutic approaches that sig-
nificantly prolong overall survival (OS) and are considered the current
standard of care for most patients with intermediate-2 and high-risk
MDS, although they have no curative potential.3,4 DNMTi have a
good toxicity profile compared with ICT, appear to be active in MDS
with unfavorable karyotype, and may therefore be of interest if used
before transplantation. Nevertheless, their role in this MDS setting has
not yet been established.
The aim of this study was to assess the impact of treatment prior
to transplantation with AZA on survival, relapse, and nonrelapse
mortality (NRM). We report an analysis of 163 patients with MDS
who underwent alloSCT following different prior treatments.
PATIENTS AND METHODS
The study was approved by the board of the French Society of Bone Marrow
Transplantation and Cell Therapy (SFGM-TC) and was conducted according
to the Declaration of Helsinki.
Patient Selection
Transplantation modalities were made as homogeneous as possible by
using the following inclusion criteria: patients older than age 18 years referred
for first alloSCT with the source of stem cells being marrow or blood from
either a sibling or an HLA-A–, -B–, -Cw–, -DR–, or –DQ–identical unrelated
donor at the allele level (so-called 10/10). Patients who received alloSCT from
an HLA-mismatched donor, cord blood, or T-cell–depleted graft, and patients
with chronic myelomonocytic leukemia were excluded.
Participating centers were asked to verify the data recorded for each
patient in the French Bone Marrow Transplantation Registry and to provide
additional information. Quality of the data was controlled by using a comput-
erized search for discrepancy errors and vigorous on-site data verification of
each file. HLA matching was cross-checked with the data of the French Bone
Marrow Donor Registry, as previously described.5
Consequently, 265 consecutive patients with MDS who underwent al-
loSCT between October 2005 and December 2009 in 24 French and Belgian
centers were identified, of whom 28 were excluded because their files lacked at
least one of the following: initial French-American-British (FAB)/WHO cate-
gory and International Prognostic Scoring System (IPSS) score, treatment
prior to transplantation, or disease status at transplantation.
Because the main objective of this study was to investigate the impact of
therapy prior to transplantation on alloSCT outcome, especially pretreatment
with AZA compared with ICT, 74 other patients were excluded because they
had received only best supportive care, including blood transfusion, hor-
mones, growth factors (erythropoietin, granulocyte colony-stimulating fac-
tor), immunosuppressive treatment, and antibiotics. The remaining 163
patients were divided into three groups according to treatment received prior
to transplantation as follows: ICT alone (ICT group; n98), AZA alone (AZA
group; n  48), and AZA preceded or followed by ICT (AZA-ICT group;
n 17), corresponding to patients for whom either treatment failed and who
received the other treatment (Fig 1). Of note, choice of pretransplantation
treatment was based on local physicians’ decisions.
Patients were also categorized according to the first treatment received
before alloSCT (ie, AZA or ICT, irrespective of whether the other treatment
was also administered before transplantation). Therefore, 51 received AZA as
their first treatment (intent-to-treat AZA group), and 112 received ICT as their
first treatment (intent-to-treat ICT group).
Patient and Donor Characteristics and
Transplantation Modalities
Morphologic classification, according to FAB and WHO classifica-
tions,6,7 was documented as a separate variable at initial diagnosis and at
time of transplantation. IPSS score at diagnosis was calculated,8 and pos-
sible progression to more advanced disease between diagnosis and trans-
plantation was recorded. Responses to treatment and disease status at
transplantation were reevaluated according to International Working
Group (IWG) 2006 criteria.9
At diagnosis (Table 1), 24 (15%) of the 163 patients had refractory
anemia, refractory anemia with ringed sideroblasts, or refractory cytopenia
with multilineage dysplasia; 52 patients (32%) had refractory anemia with
excess of blasts (RAEB-1); 74 patients (45%) had RAEB-2; and 13 patients
(8%) had RAEB in transformation/acute myeloid leukemia (RAEB-T/
AML; with marrow blasts between 20% and 30%). Cytogenetic analysis
according to IPSS classification was favorable, intermediate, or poor risk in
93, 32, and 37 patients, respectively; IPSS was low or intermediate-1 in 68
patients (lower-risk category, 42%) or intermediate-2 or high in 95 pa-
tients (higher-risk category, 58%). In AZA-treated groups, the drug was
started after a median time from diagnosis of 150 days (range, 38 to 941
days) and stopped at a median of 60 days before transplantation (range, 6
to 438 days). The median number of cycles was four (range, one to 26
cycles). According to IWG 2006 criteria,9 119 patients (73%) at transplan-
tation were in complete remission, partial remission, or marrow complete
remission, including 33 patients (69%) in the AZA group, 77 patients
(78%) in the ICT group, and nine patients (53%) in the AZA-ICT group.
Forty-four patients (27%) were nonresponders, including four who
achieved stable disease with hematologic improvement, 19 who achieved
stable disease without hematologic improvement, and 21 who had pro-
gressive disease. Overall, 67 (41%) of the 163 patients had progressed to
more aggressive disease before transplantation.
Transplantation modalities according to treatment prior to transplanta-
tion are listed in Table 2. Median time from diagnosis to transplantation was
10.0 months (range, 1.2 to 260.2 months). There were 101 men and 62 women
with a median age of 57 years (range, 18 to 69 years) at alloSCT. The donor was
an HLA sibling for 75 patients and an HLA-matched unrelated donor for 88
patients. In 33 patients, a myeloablative conditioning (MAC) regimen was
used, and in 130 patients, nonmyeloablative conditioning (RIC) was used.
Peripheral blood stem cells were used in 87% and bone marrow stem cells were
used in 13% of the patients.
Statistical Analyses
The analysis was performed on the reference date of April 1, 2011. OS was
defined as the interval from alloSCT to death, regardless of the cause of death.
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Fig 1. Flow chart for patient selection strategy. (*) Patients whose files were
missing data for at least one of the following were excluded: initial French-American-
British/WHO diagnosis, International Prognostic Scoring System score at diagnosis,
prior-to-transplantation treatment, WHO criteria, and disease status at transplanta-
tion. Allo-SCT, allogeneic stem-cell transplantation: AZA, azacitidine; BSC, best
supportive care; Chemo, chemotherapy; MDS, myelodysplastic syndrome.
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Event-free survival (EFS) was defined as survival with no evidence of relapse.
Relapse was defined as the presence of more than 5% marrow blasts and/or
reappearance of major myelodysplastic features associated with cytopenia and
evidence of autologous reconstitution when chimerism was available. NRM
was defined as death resulting from the graft procedure without evidence of
relapse. Estimated 3-year event rates were reported because the number of
events beyond 3 years was insufficient for accurate estimates. Estimated 100-
day event rates were assessed for acute graft-versus-host disease (aGVHD) and
neutrophil and platelet engraftment.
For continuous variables, medians and ranges were determined. The
assumption of normality was assessed by using the Shapiro-Wilk test. Categor-
ical variables were described by frequencies and percentages. The three prior-
to-transplantation treatment groups (AZA, ICT, and AZA-ICT) were
compared by using the 2 or the Fisher’s exact tests for categorical data. For
continuous variables, the analysis of variance or Kruskal-Wallis test was ap-
plied according to the distribution of the studied variable.
All censored criteria were calculated from the time of transplantation.
Distributions over time were estimated by the Kaplan-Meier product limit
method. The log-rank statistic was used to test the prognostic value of
patient characteristics at transplantation for the occurrence of the event.
Prior-to-transplantation treatment and variables having a significance
level of P  .15 from the univariate analyses were introduced in a multi-
variable Cox regression, with backward selection at level P  .15. Prior-
to-transplantation treatment was always included in the selection,
whatever its significance level in univariate analysis. Adjusted hazard ratios
(HRs) and 95% CIs were computed, and P  .05 was considered statisti-
cally significant.
The occurrence of relapse, NRM, and chronic GVHD (cGVHD) were
studied by using competing risk methodology. For the events of relapse
and GVHD, death without experiencing the event was considered as a
competing event. For NRM, the competing event was relapse. The cumu-
lative incidence of each event was estimated by using the Kalbfleish and
Prentice method.10 The individual prognostic value of each variable was
assessed by the Gray test (bivariate analyses were performed for compari-
son of cumulative incidence curves). Prior-to-transplantation treatment
and variables having a significance level of P  .15 in the univariate
analyses were introduced in a multivariate Fine and Gray model. Adjusted
HRs and 95% CIs were computed. Statistical analyses were performed by
using SAS software (SAS Institute, Cary, NC). For the Fine and Gray
model, the R package “cmprsk” was used (R Foundation for Statistical
Computing, Vienna, Austria; http://www.r-project.org/).












PNo. % No. % No. % No. %
Sex .16
Male 101 62 27 56 60 61 14 82
Female 62 38 21 44 38 39 3 18
FAB/WHO category .97
RA/RARS/RCMD 24 15 7 15 14 14 3 18
RAEB-1 52 32 17 35 31 32 4 24
RAEB-2 74 45 21 44 45 46 8 47
RAEB-t/AML 13 8 3 6 8 8 2 12
IPSS score .35
Low/intermediate-1 68 42 16 33 45 46 7 41
Intermediate-2/high 95 58 32 67 53 54 10 59
Cytogenetics .07
Favorable 93 57 23 48 58 59 12 71
Intermediate 32 20 9 19 18 19 5 29
High risk 37 23 16 33 21 22 0
Interval from diagnosis to
transplantation,
months .08
 6.2 31 19 4 8 26 27 1 5
6.2-9.9 47 29 16 34 27 28 4 24
10.0-21.2 49 30 17 35 24 24 8 47
 21.2 36 22 11 23 21 21 4 24
Abbreviations: AML, acute myeloid leukemia; AZA, azacitidine; FAB, French-
American-British classification; ICT, induction chemotherapy; IPSS, Interna-
tional Prognostic Scoring System; RA, refractory anemia; RAEB, refractory
anemia with excess blasts; RAEB-t, RAEB in transformation; RARS, refractory
anemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage
dysplasia.











PNo. % No. % No. % No. %
Recipient age, years .07
Median 57 60 57 58
Range 18-69 30-68 18-69 32-67
Sex mismatch 39 24 10 21 24 25 5 29 .75
Progression to more
aggressive disease  .001
No 96 59 41 85 48 49 7 41
Yes 67 41 7 15 50 51 10 59
Marrow blasts, % .01
 5 120 74 32 67 79 81 9 53
 5 43 26 16 33 18 19 8 47
Disease status .06
Responders† 119 73 33 69 77 78 9 53
Nonresponders 44 27 15 31 21 22 8 47
Donor type .77
Sibling 75 46 20 42 48 47 8 47
HLA-matched unrelated 88 54 28 58 52 51 9 53
Stem-cell source .64
Marrow 21 13 8 17 11 11 2 12
PBSCs 142 87 40 83 87 89 15 88
Karnofsky score at
transplantation .73
80-100 131 80 39 83 78 80 14 82
50-70 16 10 4 9 11 11 1 6
Missing 16 5 9 2
Reason for RIC .55
Age  50 years 96 74 30 75 59 79 9 60
Comorbidities 15 11 4 10 8 11 2 13
Protocol driven 14 11 5 13 5 7 3 20
Missing 5 1 3 1
Conditioning .41
MAC 33 20 8 17 23 23 2 12
RIC 130 80 40 83 75 77 15 88
ATG .11
No 56 34 18 37 36 37 2 12
Yes 107 66 30 63 62 63 15 88
TBI .41
No 125 77 38 79 73 75 14 82
Yes 38 23 10 21 25 25 3 18
Abbreviations: ATG, antithymocyte globulin; AZA, azacitidine; ICT, induction
chemotherapy; MAC, myeloablative conditioning; PBSC, peripheral blood
stem cell; RIC, reduced-intensity conditioning; TBI, total-body irradiation.
Sex mismatch is defined as a male recipient who received graft from a
female donor.
†Responders included patients with complete remission, partial remission,
or marrow complete remission.
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RESULTS
At the date of analysis (April 1, 2011), median follow-up was 38.7
months (range, 15.2 to 65.6 months). All but seven patients had
obtained neutrophil engraftment after a median time of 16 days
(range, 0 to 70 days). Fifty-three patients (33%) had developed grade 2
to 4 aGVHD, including 21 patients (13%) with grade 3 to 4. Of the 143
evaluable patients who survived more than 100 days, 75 (52%) had
developed cGVHD, including 44 (31%) with extensive cGVHD. For
the whole patient group, median 3-year OS, EFS, relapse, and NRM
were 48%, 42%, 37%, and 21%, respectively.
Univariate Analysis
As expected, among all at diagnosis and/or at transplantation
characteristics that were studied, high-risk cytogenetic profile ad-
versely influenced OS, EFS, and relapse P .001 for all). Patients who
received grafts from cytomegalovirus-seropositive donors tended to
relapse more often than other patients (P .05), although those who
received alloSCT from an HLA-matched unrelated donor had a lower
NRM rate (P .04).
Grade 2 to 4 aGVHD was correlated more positively with bone
marrow stem cells (52%) than with peripheral blood stem cells (29%;
P  .03). The type of conditioning, either MAC or RIC, affected also
the rate of aGVHD (58% v 28%; P .01).
Table 3. Univariate Analysis by Key Subsets: 3-Year OS and EFS, Relapse








% P % P % P† % P†
Sex .18 .32 .68 .33
Male 101 43 39 38 24
Female 62 55 49 35 17
Age, years .53 .49 .98 .35
 57.6 80 47 46 36 19
 57.6 83 49 40 38 23
FAB/WHO .60 .71 .32 .72
RA/RARS/RCMD 24 54 54 22 25
RAEB-1 52 34 27 48 26
RAEB-2 74 53 46 38 16
RAEB-t/AML 13 57 53 23 24
IPSS .38 .34 .10 .24
Low/intermediate-1 68 52 40 35 27
Intermediate-2/high 95 46 43 40 17
Cytogenetics  .001  .001  .001 .71
Favorable 93 60 49 27 24
Intermediate 32 44 50 37 17
High risk 37 21 22 59 19
Sex mismatch .88 .82 .65 .71
No 123 46 44 35 22
Yes 39 52 38 45 18
Progression to more
aggressive
disease .84 .46 .86 .84
No 96 48 42 38 21
Yes 67 48 42 36 21
Marrow blasts, % .25 .12 .25 .84
 5 135 48 44 36 21
 5 27 43 33 45 22
Treatment prior to
alloSCT
AZA alone v ICT
alone
.65 .67 .78 .76
AZA alone 48 58 52 40 17
ICT alone 98 51 45 35 19
AZA alone v AZA
plus ICT
.032 .038 .31 .041
AZA alone 48 58 52 40 17
AZA plus ICT 17 35 29 37 35
Interval from diagnosis
to transplantation,
months .90 .84 .42 .18
 10 81 49 44 39 16
 10 82 54 46 29 24
Disease status .07 .07 .67 .18
Responders 119 49 45 37 19
Nonresponders 44 42 36 38 27
Donor age, years .06 .08 .91 .08
 44.9 81 40 67 40 27
 44.9 80 56 47 33 16
Donor type .10 .11 .74 .04
Sibling 75 51 51 37 14
HLA-matched
unrelated
88 44 36 37 27
Stem-cell source .24 .48 .47 .91
Marrow 21 38 38 43 19
PBSCs 142 49 43 36 21
(continued in next column)
Table 3. Univariate Analysis by Key Subsets: 3-Year OS and EFS, Relapse








% P % P % P† % P†
Recipient CMV
serostatus
.60 .79 .99 .64
Negative 73 45 40 39 22
Positive 90 50 45 35 20
Donor CMV serostatus .16 .07 .05 .86
Negative 85 41 33 46 22
Positive 78 55 55 26 19
Conditioning .40 .63 .74 .76
MAC 33 50 45 37 18
RIC 130 47 42 37 22
ATG .79 .69 .59 .84
No 56 48 43 34 22
Yes 107 48 42 38 20
TBI .13 .18 .49 .35
No 125 51 46 36 19
Yes 38 36 31 42 27
Abbreviations: alloSCT, allogeneic stem-cell transplantation; AML, acute
myeloid leukemia; ATG, antithymocyte globulin; AZA, azacitidine; CMV, cyto-
megalovirus; EFS, event-free survival; FAB, French-American-British [classifi-
cation]; ICT, induction chemotherapy; IPSS, International Prognostic Scoring
System; MAC, myeloablative conditioning; NRM, nonrelapse mortality; OS,
overall survival; PBSC, peripheral blood stem cell; RA, refractory anemia;
RAEB, refractory anemia with excess blasts; RAEB-t, RAEB in transition;
RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia
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As depicted in Table 3, none of the following variables seemed to
influence the outcome of alloSCT: recipient age and sex, sex mis-
match, donor age, stem-cell source, recipient and conditioning regi-
men type (ie, intensity, antithymoglobulin, or total-body irradiation),
initial FAB/WHO subgroups, IPSS at diagnosis, progression to more
advanced disease at time of transplantation, time between diagnosis
and transplantation, and marrow blasts at transplantation. Of note,
disease status at transplantation tended to influence OS and EFS, with
P values of .07 for each.
Outcome According to
Prior-to-Transplantation Treatment
In patients treated with AZA alone and ICT alone before trans-
plantation, 3-year OS was 58% versus 51% (P .65), 3-year EFS was
52% versus 45% (P .67), cumulative incidence of relapse was 40%
versus 37% (P  .76), and NRM was 19% versus 20% (P  .78),
respectively (Fig 2). Conversely, when compared with patients in
the AZA group, those who received AZA plus ICT had lower rates
of 3-year OS (35%; P  .035), EFS (29%; P  .038), and NRM
(35%; P  .041).
The type of treatment before alloSCT had no significant impact
on the incidence and severity of aGVHD (data not shown). However,
higher cumulative incidence of extensive cGVHD was observed in the
AZA-ICT group (57%) compared with the ICT-alone group (26%)
and AZA-alone group (31%; P .049).
Outcome According to First
Prior-to-Transplantation Treatment
In the intent-to-treat AZA and intent-to-treat ICT groups, 3-year
OS was 58% versus 49% (P  .39), 3-year EFS was 52% versus 43%
(P .40), relapse rate was 41% versus 37% (P .71), and NRM was
16% versus 23% (P .39), respectively.
Multivariate Analysis
Multivariate analysis confirmed the absence of significant differ-
ences between AZA and ICT groups in terms of OS (HR, 1.41; 95% CI,
BA
AZA alone: HR = 1
ICT alone v AZA alone: HR = 1.41 (95% CI, 0.83 to 2.42); P = ns
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AZA alone: HR = 1
ICT alone v AZA alone: HR = 1.48 (95% CI, 0.90 to 2.44); P = ns
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AZA alone: HR = 1
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AZA alone 48 43 37 33 31 28 22 15 11 9 7 0
ICT alone 98 87 77 72 65 58 54 51 42 35 30 0
ICT−AZA 17 14 10 7 6 5 5 5 2 2 2 0
0 200 400 600 800 1,000
Fig 2. Kaplan-Meier estimates of (A) 3-year overall survival, (B) 3-year event-free survival, (C) cumulative incidence of 3-year relapse, and (D) nonrelapse mortality
(NRM) in 163 patients, according to the prior-to-transplantation treatment received. AZA, azacitidine; HR, hazard ratio; ICT, induction chemotherapy; ns, not significant.
Treatment Before Allogeneic SCT for Myelodysplastic Syndromes
www.jco.org © 2012 by American Society of Clinical Oncology 4537
139.165.96.129
Information downloaded from jco.ascopubs.org and provided by at UNIV/ MEDECINE/ LIEG/22827242 on July 8, 2013 from
Copyright © 2012 American Society of Clinical Oncology. All rights reserved.
0.83 to 2.42; P .202), EFS (HR, 1.48; 95% CI, 0.90 to 2.44; P .127),
cumulative incidence of relapse (HR, 1.35; 95% CI, 0.73 to 2.46; P
.340), and NRM (HR, 1.23; 95% CI, 0.55 to 2.76; P .610). However,
receiving sequential treatment of AZA followed or preceded by ICT
was found to adversely influence both OS (HR, 3.08; 95% CI, 1.38 to
6.86; P .006) and EFS (HR, 2.72; 95% CI, 1.38 to 5.34; P .014). In
addition, there was a trend toward a negative impact of AZA-ICT on
NRM (HR, 2.50; 95% CI, 0.89 to 7.05; P  .082). NRM was also
influenced by HLA-matched unrelated donor (HR, 2.17; 95% CI, 1.05
to 4.49; P .036).
When intent-to-treat groups were considered, multivariate anal-
yses confirmed the absence of differences between intent-to-treat AZA
and intent-to-treat ICT groups in terms of OS (HR, 1.67; 95% CI, 0.93
to 2.65; P  .091), EFS (HR, 1.44; 95% CI, 0.89 to 2.44; P  .137),
cumulative incidence of relapse (HR, 1.38; 95% CI, 0.76 to 2.51;
P .291), and NRM (HR, 1.41; 95% CI, 0.63 to 3.14; P .400).
As expected, high-risk cytogenetic profile had a detrimental im-
pact on OS (HR, 1.93; 95% CI, 1.45 to 2.57; P .001), EFS (HR, 1.82;
95% CI, 1.39 to 2.38; P .001), and relapse (HR, 1.87; 95% CI, 1.36 to
2.57; P  .001). EFS was also influenced by donor age 44.9 years or
older (HR, 1.59; 95% CI, 1.02 to 2.44; P .042). Results for OS, EFS,
relapse, and NRM are summarized in Table 4.
DISCUSSION
In this series, which to the best of our knowledge is the largest study on
the use of AZA before transplantation in patients with MDS, we found
post-transplantation outcome (in terms of OS, EFS, cumulative inci-
dence of relapse, and NRM) in patients who received AZA alone
before transplantation comparable to that of patients treated with ICT
alone before alloSCT. The same results were observed when the first
treatment received before alloSCT was considered.
The study was started in October 2005, corresponding to the
date when AZA became available in France, and stopped on De-
cember 2009, which permitted more than 1 year of follow-up. We
did not include patients who received transplantation before Oc-
tober 2005 because transplantation modalities and patient out-
comes changed over time.11-13 To make the study population as
homogeneous as possible, we included only patients who received
alloSCT from an HLA sibling or HLA allelically matched unrelated
donor (10/10).
Single-agent therapy with AZA may be of value in stabilizing the
disease or even reverting it to an earlier stage and allowing time for
patients to reach transplantation since, in our study, only 15% of
patients referred to alloSCT after AZA alone had progressed to more
advanced disease before transplantation compared with 51% of those
who had received ICT alone. Lu¨bbert et al14 suggested that, outside the
alloSCT setting, decitabine could be a valid alternative to standard
chemotherapy in elderly patients with MDS/AML before alloSCT.
Furthermore, in a larger retrospective study comparing decitabine
agents with ICT in patients with AML or MDS, Kantarjian et al15
showed better OS in the patients treated with decitabine compared
with historic controls receiving ICT because of lower early mortality
rather than response rate. Nevertheless, the retrospective nature of
those studies does not allow any firm conclusion regarding a beneficial
effect of DNMTi.
Table 4. Multivariate Analyses
Characteristics
3-Year OS 3-Year EFS 3-Year Relapse 3-Year NRM
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Recipient age, years
 57.6 1 — — —
 57.6 0.63 0.37 to 1.07 .089
Cytogenetics
Low/intermediate 1 1 1 —
High risk 1.93 1.45 to 2.57  .001 1.82 1.39 to 2.38  .001 1.87 1.36 to 2.57  .001
Prior treatment
AZA alone 1 1 1 1
ICT alone v AZA alone 1.41 0.83 to 2.42 .202 1.48 0.90 to 2.44 .127 1.35 0.73 to 2.46 .340 1.23 0.55 to 2.76 .610
ICT-AZA v AZA alone 3.08 1.38 to 6.86 .006 2.72 1.38 to 5.34 .014 1.87 0.69 to 5.06 .220 2.50 0.89 to 7.05 .082
Disease status at transplantation
Responders 1 1 — —
Nonresponders 1.37 0.83 to 2.45 .215 1.36 0.86 to 2.17 .193
Donor age, years
 44.9 — 1 — —
 44.9 1.59 1.02 to 2.44 .042
Donor type — 1 1
Sibling HLA-matched
unrelated 1.31 0.77 to 2.22 .320 — 2.17 1.05 to 4.49 .036
Donor CMV serostatus
Negative — 1 1 —
Positive 0.79 0.51 to 1.22 .287 0.63 0.36 to 1.10 .110
NOTE. Prior-to-transplantation treatment and variables having a significance level of P  .15 in the univariate analyses were introduced in a multivariate model.
Abbreviations: AZA, azacitidine; CMV, cytomegalovirus; EFS, event-free survival; HR, hazard ratio; ICT, induction chemotherapy; NRM, nonrelapse mortality; OS,
overall survival.
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Few studies have investigated DNMTi before alloSCT.14,16-18
Field et al,17 in a retrospective series of 30 patients with MDS and
patients without MDS treated with AZA alone or in association with
chemotherapy or other drugs before alloSCT and compared with 24
patients who did not receive AZA, showed a comparable 1-year OS
and EFS in the two groups. They also found a trend toward lower
incidence of relapse in the AZA group. The population heteroge-
neity as well as the heterogeneity of treatment received before
alloSCT in the group that was not treated with AZA (13 patients
received transplantation without prior treatment) may be an ex-
planation for the lower relapse rate in patients who received AZA.
In this study, we did not observe any difference in relapse rate
between patients treated with AZA and those treated with ICT.
Although never studied in a prospective manner, relapse is
thought to be more likely to occur after RIC.19 In this study, and in
agreement with what has been reported by Buchholz et al,20 there was
a lower rate of relapse after RIC than after MAC. The explanation for
this result may be that all the patients in our study received a cytore-
ductive treatment prior to transplantation.
Seventeen patients received AZA preceded (n  15) or fol-
lowed (n 2) by ICT. These patients had worse outcomes in terms
of OS and EFS than other patients who received AZA alone or ICT
alone before transplantation. This inferior outcome could result
from the fact that patients who required both treatments had more
resistant disease with more frequent relapse post-transplantation
and/or to the fact that they had increased NRM because they
received more treatment before transplantation. It is of note that
50% of patients treated with both AZA and ICT were responders at
transplantation and none of them had a high-risk cytogenetic
profile at diagnosis. In addition, they had similar rates of post-
transplantation relapse compared with the other groups of pa-
tients. In contrast, there was a trend toward higher NRM rate
(P  .082) and more extensive cGVHD compared with patients
belonging to the other groups. These results are in line with our
previous finding that intensification of the conditioning regimen
before alloCST in patients with therapy-related MDS or AML
experienced a detrimental effect on post-transplantation outcome
without reduction in the relapse rate.1
In conclusion, for the purpose of reducing the tumor burden
before alloSCT, azacitidine seems to be a valid therapeutic approach
and showed comparative OS, EFS, relapse incidence, and NRM when
compared with ICT. AlloSCT in patients who required both AZA and
ICT had less satisfactory outcomes.
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